{
    "clinical_study": {
        "@rank": "38392", 
        "arm_group": [
            {
                "arm_group_label": "Ibuprofen 5% topical gel", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Topical gel vehicle", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sodium lauryl sulfate 0.2%", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sodium chloride solution 0.9% (saline)", 
                "arm_group_type": "Sham Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine the potential of Ibuprofen 5% Topical Gel and its vehicle gel to\n      cause irritation after repeated topical application to the healthy skin of human subjects\n      under controlled conditions."
        }, 
        "brief_title": "Ibuprofen 5% Topical Gel CIPT", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Healthy male and/or female subjects (to be confirmed by medical history) 18 years of age\n        or older, female subjects of childbearing potential and males who are using an acceptable\n        form of birth control, subjects who are free of any systemic or dermatologic disorder\n\n        Exclusion Criteria:\n\n        Have skin disease at the application site, not willing to stop use of systemic or topical\n        analgesics, corticosteroids, or antihistamines, unwilling or unable to stop use of\n        sunscreens, creams, or similar products on the back during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771822", 
            "org_study_id": "B3491004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ibuprofen 5% topical gel", 
                "description": "0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions", 
                "intervention_name": "Ibuprofen 5% topical gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Topical gel vehicle", 
                "description": "0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions", 
                "intervention_name": "Topical gel vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sodium lauryl sulfate 0.2%", 
                "description": "0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions", 
                "intervention_name": "Sodium lauryl sulfate 0.2%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sodium chloride solution 0.9% (saline)", 
                "description": "0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions", 
                "intervention_name": "Sodium chloride solution 0.9% (saline)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "cumulative irritancy patch test (CIPT)", 
        "lastchanged_date": "February 27, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3491004&StudyName=Ibuprofen%205%25%20Topical%20Gel%20CIPT"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Carlstadt", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07652"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Cumulative Irritancy Patch Test (Cipt) of Ibuprofen 5% Topical Gel in Human Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assessment of local skin irritation at patch sites", 
            "safety_issue": "Yes", 
            "time_frame": "Daily for 21 days, Days 2 through 22"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771822"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Days 1 through 22, + 28 days after last product administration"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}